INVESTOR RELATIONS

OVERVIEW

Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs. Amarin's development pipeline includes a program in Huntington's disease and Myasthenia Gravis, two programs in Parkinson's disease, one in epilepsy, one in memory and a series of programs in cardiovascular disease.

Market Listings For Amarin Stock

Amarin is listed on the Nasdaq capital market (ticker: AMRN).

INVESTOR RELATIONS

Recent News

more >>

Upcoming Events

more >>

There are currently no events scheduled

INVESTOR RELATIONS

Investor Relations Contacts

Amarin Corporation plc
First Floor, Block 3, The Oval
Ballsbridge, Dublin 4, Ireland
Darren Cunningham

t: +353 (0) 1 669 9020
f: +353 (0) 1 669 9028
e: investor.relations@amarincorp.com

Company Registrars

Lloyds TSB Registrars,
The Causeway,
Worthing,
West Sussex
BN99 6DA, UK

Citi, 
Depositary Receipt Services, 
388 Greenwich St., 
New York, NY 10013, USA

This page was last updated on July, 1 2008.